Engineering Human GBA1-mRNA for Gaucher Disease: Enhanced Lysosomal Enzyme Restoration

Study Background and Research Question

Gaucher disease (GD) is a lysosomal storage disorder caused by loss-of-function mutations in the GBA1 gene, encoding the enzyme β-glucocerebrosidase (GCase). Deficiency of GCase results in progressive accumulation of glucosylceramide and glucosylsphingosine within macrophages, leading to organomegaly, cytopenias, and skeletal complications. Current therapies—enzyme replacement therapy (ERT) and substrate reduction therapy (SRT)—partially alleviate disease burden but are hampered by high cost, short half-lives, immunogenicity, and limited central nervous system penetration. The referenced study (Feng et al., 2026) addressed whether engineering mRNA constructs encoding human GBA1 could yield sustained, lysosomally targeted GCase expression as a novel therapeutic modality for GD, potentially overcoming key drawbacks of ERT.

Key Innovation from the Reference Study

The primary innovation lies in the rational optimization of human GBA1 mRNA for therapeutic use. The research team systematically modified untranslated regions (UTRs), codon usage, and poly(A) tail lengths to maximize mRNA stability and translational efficiency. Using both in vitro and in vivo models, they demonstrated that these optimizations produced over six-fold greater GCase activity than unoptimized constructs, with a notable increase in protein half-life and functional delivery to lysosomes. The protocol's core novelty is leveraging synthetic mRNA encapsulated in lipid nanoparticles (LNPs) to transiently produce enzyme within host cells, thus mimicking the endogenous biosynthetic pathway more closely than exogenous recombinant protein therapies (Feng et al., 2026).

Methods and Experimental Design Insights

To systematically optimize mRNA constructs, the authors varied 5’ and 3’ UTR sequences, codon composition, and poly(A) tail lengths, then transfected HEK293T and RAW264.7 cells to assay for GCase expression and activity. Half-life was monitored using cycloheximide-chase experiments. Subcellular localization of the expressed enzyme was visualized by immunofluorescence, confirming lysosomal targeting. Functionality was assessed in GBA1-knockout (KO) cells by measuring cellular morphology and substrate accumulation. For in vivo validation, a single dose of hGBA1-mRNA-LNP was administered to wild-type FVB mice, and GCase activity was quantified in liver and spleen tissue lysates using a fluorescent substrate-based assay at 72 hours post-injection.

Protocol Parameters

• mRNA construct optimization: Systematic testing of UTRs, codon usage, and poly(A) tail lengths; selection based on in vitro translation and stability.
• Transfection conditions: HEK293T and RAW264.7 cells, optimized lipid-based delivery; assessment at 24 and 48 hours post-transfection.
• β-Glucocerebrosidase activity assay: Quantitative measurement using fluorogenic substrate (e.g., 4-Methylumbelliferyl-β-D-Glucopyranoside) at nanomolar to low micromolar concentrations, emission measured at 445–454 nm.
• In vivo administration: Single intravenous injection of hGBA1-mRNA-LNP; tissue collection at 72 hours for enzymatic assay.

Core Findings and Why They Matter

The optimized hGBA1-mRNA achieved dramatic improvements in GCase expression, yielding over six times the enzymatic activity of the least efficient constructs at 24 hours post-transfection. The protein exhibited a half-life exceeding 54 hours, ensuring sustained lysosomal activity. In GBA1-KO cell models, hGBA1-mRNA restored normal lysosomal morphology and reduced pathological substrate accumulation, indicating functional correction at the cellular level. Importantly, in vivo administration of hGBA1-mRNA-LNP resulted in detectable GCase activity in both liver and spleen tissue of treated mice, demonstrating successful delivery and translation. These findings support mRNA-LNP as a promising alternative to ERT, with potential for less frequent dosing, reduced immunogenicity, and improved tissue distribution (Feng et al., 2026).

Comparison with Existing Internal Articles

Several internal resources contextualize the significance of these results within the broader landscape of lysosomal enzyme research and assay optimization:

• "4-Methylumbelliferyl-β-D-Glucopyranoside: Precision Tools for Lysosomal Enzyme Activity Assays" highlights the use of 4-MUG as a standard substrate in β-glucocerebrosidase activity assays and discusses assay optimization strategies relevant to the experimental protocols used in the reference study.
• "Transforming Lysosomal Enzyme Assays in Gaucher Disease Research" explores how advances in fluorescent substrate-based assays, including those using 4-MUG, facilitate translational research and support the development of mRNA therapeutics.
• "Optimized GBA1-mRNA Restores Lysosomal Function in Gaucher Models" provides additional mechanistic insight into mRNA platform development and aligns closely with the innovation described by Feng et al., reinforcing the translational impact of mRNA-based approaches for lysosomal storage disorders.

These articles converge on the importance of sensitive, quantitative lysosomal enzyme activity assays—such as those enabled by 4-MUG—in both basic research and therapeutic development pipelines.

Limitations and Transferability

While the study demonstrates robust mRNA-mediated GCase expression in cellular and mouse models, several challenges remain for clinical translation. First, the single-dose in vivo experiments do not address long-term safety, repeated dosing, or immune response risks specific to mRNA-LNP platforms. Tissue distribution and blood-brain barrier penetration were not directly measured, leaving open the question of efficacy in neuronopathic GD subtypes. Furthermore, while lysosomal targeting and substrate clearance were confirmed in vitro, in vivo substrate reduction and functional outcomes require further evaluation in disease models. These limitations underscore the need for extended preclinical and clinical studies before this approach can be broadly adopted.

Research Support Resources

For researchers aiming to replicate or extend these workflows, reliable enzymatic activity quantification is essential. 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG, SKU C3426) is widely used as a fluorogenic substrate for β-glucosidase and β-glucocerebrosidase activity assays in both in vitro and tissue-based studies. According to the product information, 4-MUG is compatible with a range of biological systems and can be stored at -20°C to maintain stability. When developing or optimizing lysosomal enzyme activity assays, APExBIO's high-purity 4-MUG substrate provides reproducible results and supports sensitive detection—key factors in translational research pipelines such as those described in the reference study.